1
|
Ducreux M, Abou-Alfa GK, Bekaii-Saab T, Berlin J, Cervantes A, de Baere T, Eng C, Galle P, Gill S, Gruenberger T, Haustermans K, Lamarca A, Laurent-Puig P, Llovet JM, Lordick F, Macarulla T, Mukherji D, Muro K, Obermannova R, O'Connor JM, O'Reilly EM, Osterlund P, Philip P, Prager G, Ruiz-Garcia E, Sangro B, Seufferlein T, Tabernero J, Verslype C, Wasan H, Van Cutsem E. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022. ESMO Open 2023; 8:101567. [PMID: 37263081 PMCID: PMC10245111 DOI: 10.1016/j.esmoop.2023.101567] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2023] [Revised: 04/20/2023] [Accepted: 04/24/2023] [Indexed: 06/03/2023] Open
Abstract
This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is mandatory to ensure an optimal diagnosis and staging of HCC, planning of curative and therapeutic options, including surgical, embolisation, ablative strategies, or systemic therapy. Furthermore, in many patients with HCC, underlying liver cirrhosis represents a challenge and influences the therapeutic options.
Collapse
Affiliation(s)
- M Ducreux
- Université Paris-Saclay, Gustave Roussy, Villejuif, France.
| | - G K Abou-Alfa
- Memorial Sloan Kettering Cancer Center, New York; Weill Cornell College of Medicine, New York, USA; Trinity College Dublin, Dublin, Ireland
| | | | - J Berlin
- Vanderbilt-Ingram Cancer Center, Nashville, USA
| | - A Cervantes
- INCLIVA, Biomedical Research Institute, Hospital Clínico Universitario, University of Valencia, Valencia, Spain
| | - T de Baere
- Université Paris-Saclay, Gustave Roussy, Villejuif, France
| | - C Eng
- Vanderbilt-Ingram Cancer Center, Nashville, USA
| | - P Galle
- University Medical Center Mainz, Mainz, Germany
| | - S Gill
- BC Cancer/University of British Columbia, Vancouver, Canada
| | - T Gruenberger
- Clinic Favoriten, HPB Center Health Network Vienna and Sigmund Freud University, Medical School, Vienna, Austria
| | - K Haustermans
- University Hospitals Gasthuisbergs, Leuven; Katholieke Universiteit Leuven, Leuven, Belgium
| | - A Lamarca
- Department of Oncology, OncoHealth Institute, Fundación Jiménez Díaz University Hospital, Madrid, Spain; Department of Medical Oncology, The Christie NHS Foundation, Manchester; Division of Cancer Sciences, University of Manchester, Manchester, UK
| | - P Laurent-Puig
- Institut du cancer Paris CARPEM, APHP, Georges Pompidou Hospital, Université Paris Cité, Paris, France
| | - J M Llovet
- Icahn School of Medicine at Mount Sinai, Mount Sinai Liver Cancer Program, New York, USA; Institut d'Investigacions Biomèdiques August Pi i Sunyer Hospital Clínic, Universitat de Barcelona, Barcelona; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain
| | - F Lordick
- University of Leipzig Medical Center, Comprehensive Cancer Center Central Germany, Leipzig, Germany
| | - T Macarulla
- Vall d'Hebron Hospital Campus, Barcelona, Spain; Institute of Oncology, IOB-Quiron, UVic-UCC, Barcelona, Spain
| | - D Mukherji
- American University of Beirut, Beirut, Lebanon
| | - K Muro
- Aichi Cancer Center Hospital, Nagoya, Japan
| | - R Obermannova
- Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno, Czech Republic
| | - J-M O'Connor
- Instituto Alexander Fleming, Buenos Aires, Argentina
| | - E M O'Reilly
- Memorial Sloan Kettering Cancer Center, New York; Weill Cornell College of Medicine, New York, USA
| | - P Osterlund
- Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden; Tampere University Hospital, University of Tampere, Tampere, Finland
| | - P Philip
- Henry Ford Cancer Institute, Departments of Oncology and Pharmacology, Wayne State University, Detroit, USA
| | - G Prager
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | | | - B Sangro
- Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain
| | | | - J Tabernero
- Vall d'Hebron Hospital Campus and Institute of Oncology, IOB-Quiron, UVic-UCC, Barcelona, Spain
| | - C Verslype
- University Hospitals Gasthuisbergs, Leuven; Katholieke Universiteit Leuven, Leuven, Belgium
| | - H Wasan
- Hammersmith Hospital, Imperial College London, London, UK
| | - E Van Cutsem
- University Hospitals Gasthuisbergs, Leuven; Katholieke Universiteit Leuven, Leuven, Belgium
| |
Collapse
|
2
|
Linardou H, Adjei AA, Bajpai J, Banerjee S, Berghoff AS, Mathias CC, Choo SP, Dent R, Felip E, Furness AJS, Garassino MC, Garralda E, Konsoulova-Kirova A, Letsch A, Menzies AM, Mukherji D, Peters S, Sessa C, Tsang J, Yang JCH, Garrido P. Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey. ESMO Open 2023; 8:100781. [PMID: 36842299 PMCID: PMC10163010 DOI: 10.1016/j.esmoop.2023.100781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2022] [Revised: 01/04/2023] [Accepted: 01/04/2023] [Indexed: 02/26/2023] Open
Abstract
BACKGROUND Following a European Society for Medical Oncology Women for Oncology (ESMO W4O) survey in 2016 showing severe under-representation of female oncologists in leadership roles, ESMO launched a series of initiatives to address obstacles to gender equity. A follow-up survey in October 2021 investigated progress achieved. MATERIALS AND METHODS The W4O questionnaire 2021 expanded on the 2016 survey, with additional questions on the impact of ethnicity, sexual orientation and religion on career development. Results were analysed according to respondent gender and age. RESULTS The survey sample was larger than in 2016 (n = 1473 versus 482), especially among men. Significantly fewer respondents had managerial or leadership roles than in 2016 (31.8% versus 51.7%). Lack of leadership development for women and unconscious bias were considered more important in 2021 than in 2016. In 2021, more people reported harassment in the workplace than in 2016 (50.3% versus 41.0%). In 2021, ethnicity, sexual orientation and religion were considered to have little or no impact on professional career opportunities, salary setting or related potential pay gap. However, gender had a significant or major impact on career development (25.5% of respondents), especially in respondents ≤40 years of age and women. As in 2016, highest ranked initiatives to foster workplace equity were promotion of work-life balance, development and leadership training and flexible working. Significantly more 2021 respondents (mainly women) supported the need for culture and gender equity education at work than in 2016. CONCLUSIONS Gender remains a major barrier to career progression in oncology and, although some obstacles may have been reduced since 2016, we are a long way from closing the gender gap. Increased reporting of discrimination and inappropriate behaviour in the workplace is a major, priority concern. The W4O 2021 survey findings provide new evidence and highlight the areas for future ESMO interventions to support equity and diversity in oncology career development.
Collapse
Affiliation(s)
- H Linardou
- 4th Oncology Department & Comprehensive Clinical Trials Centre, Metropolitan Hospital, Athens, Greece.
| | | | - J Bajpai
- Tata Memorial Centre, Homi-bhabha National Institute, Mumbai, India
| | - S Banerjee
- The Royal Marsden NHS Foundation Trust, Institute of Cancer Research, London, UK
| | - A S Berghoff
- Division of Oncology, Department of Medicine 1, Medical University of Vienna, Vienna, Austria
| | | | - S P Choo
- Curie Oncology Singapore, National Cancer Centre Singapore
| | - R Dent
- National Cancer Center Singapore, Duke-NUS Medical School, Singapore
| | - E Felip
- Medical Oncology Department, Vall d'Hebron University Hospital, Thoracic Oncology and H&N Cancer Unit, Vall d'Hebron Institute of Oncology (VHIO), UVic-UCC, Barcelona, Spain
| | | | - M C Garassino
- University of Chicago Medicine & Biological Sciences, Section of Hematology/Oncology, Chicago, USA
| | - E Garralda
- Early Drug Development Unit, VHIO-Vall d'Hebron Institute of Oncology, HUVH-Vall d'Hebron University Hospital, Barcelona, Spain
| | | | - A Letsch
- Department of Medicine II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany
| | - A M Menzies
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia
| | - D Mukherji
- Clemenceau Medical Center Dubai, Dubai, United Arab Emirates
| | - S Peters
- Oncology Department-CHUV, Lausanne University, Lausanne
| | - C Sessa
- Ente Ospedaliero Cantonale, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - J Tsang
- Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China
| | - J C-H Yang
- Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan
| | - P Garrido
- Universidad de Alcalá, Medical Oncology Department, IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain
| |
Collapse
|
3
|
Shamseddine A, Turfa R, Elias C, Kattan J, Mukherji D, Temraz S, Alqasem K, Amarin R, Al Awabdeh T, Deeba S, Mohamad I, Daoud F, Al Masri M, Dabous A, Hushki A, Jaber O, Charafeddine M, Al Darazi M, Zeidan Y, Geara F. P-258 Chemoimmunotherapy in the context of total neoadjuvant therapy (TNT) in patients with locally advanced rectal cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
4
|
Fundytus A, Wells JC, Sharma S, Hopman WM, Del Paggio JC, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, Booth CM. Industry Funding of Oncology Randomised Controlled Trials: Implications for Design, Results and Interpretation. Clin Oncol (R Coll Radiol) 2021; 34:28-35. [PMID: 34479769 DOI: 10.1016/j.clon.2021.08.003] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Revised: 06/24/2021] [Accepted: 08/02/2021] [Indexed: 11/19/2022]
Abstract
AIMS Most randomised controlled trials (RCTs) in oncology are now funded by the pharmaceutical industry. We explore the extent to which RCT design, results and interpretation differ between industry-funded and non-industry-funded RCTs. MATERIALS AND METHODS In this cross-sectional analysis, a structured literature search was used to identify all oncology RCTs published globally during 2014-2017. Industry funding was identified based on explicit statements in the publication. Descriptive statistics were used to compare elements of trial methodology and output between industry- and non-industry-funded RCTs. RESULTS The study sample included 694 RCTs; 71% were funded by industry. Industry-funded trials were more likely to test systemic therapy (97% versus 62%; P < 0.001), palliative-intent therapy (71% versus 41%; P < 0.001) and study breast cancer (20% versus 12%; P < 0.001). Industry-funded trials were larger (median sample size 474 versus 375; P < 0.001) and more likely to meet their primary end point (49% versus 41%; P < 0.001). Among positive trials, there were no differences in the magnitude of benefit between industry- and non-industry-funded RCTs. Trials funded by industry were published in journals that had a significantly higher median impact factor (21, interquartile range 7, 28) than non-industry-funded trials (impact factor 12, interquartile range 5, 24; P = 0.005); this persisted when adjusted for whether a trial was positive or negative. CONCLUSIONS The vast majority of oncology RCTs are now funded by industry. Industry-funded trials are larger, more likely to be positive, predominantly test systemic therapies in the palliative setting and are published in higher impact journals than trials without industry support.
Collapse
Affiliation(s)
- A Fundytus
- Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Ontario, Canada; Department of Oncology, Queen's University, Kingston, Ontario, Canada
| | - J C Wells
- Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Ontario, Canada; Department of Oncology, Queen's University, Kingston, Ontario, Canada
| | - S Sharma
- Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Ontario, Canada
| | - W M Hopman
- Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada
| | - J C Del Paggio
- Department of Oncology, Northern Ontario School of Medicine, Thunder Bay, Ontario, Canada
| | - B Gyawali
- Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Ontario, Canada; Department of Oncology, Queen's University, Kingston, Ontario, Canada; Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada
| | - D Mukherji
- American University of Beirut Medical Center, Beirut, Lebanon
| | - N Hammad
- Department of Oncology, Queen's University, Kingston, Ontario, Canada
| | - C S Pramesh
- Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
| | - A Aggarwal
- Institute of Cancer Policy, King's College London, London, UK; London School of Hygiene and Tropical Medicine, London, UK
| | - R Sullivan
- Institute of Cancer Policy, King's College London, London, UK
| | - C M Booth
- Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Ontario, Canada; Department of Oncology, Queen's University, Kingston, Ontario, Canada; Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada.
| |
Collapse
|
5
|
Shamseddine A, Zeidan Y, Bouferraa Y, Turfa R, Kattan J, Mukherji D, Temraz S, Alqasem K, Amarin R, Al Awabdeh T, Deeba S, Doughan S, Mohamad I, Elkhaldi M, Daoud F, Al Masri M, Dabous A, Hushki A, Charafeddine M, Al Darazi M, Geara F. SO-30 Efficacy and safety of neoadjuvant short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma: Averectal study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.054] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
6
|
Nassar F, Hadla R, El Helou R, Kreidieh F, Bejjany R, Mukherji D, Shamseddine A, Nasr R, Temraz S. P-232 Prognostic inflammatory and microRNA biomarkers in stage IV colorectal cancer patients. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
7
|
El Husseini Z, Kreidieh M, Haibe Y, Mukherji D, Temraz S, Charafeddine M, Shamseddine A. P-134 Total neoadjuvant therapy in locally advanced rectal cancer patients: A tertiary medical center experience. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
8
|
Kreidieh M, El Chami A, Haddadin F, Al Darazi M, Charafeddine M, Haydar A, Muallem N, Ershaid F, Faraj W, Khalifeh M, Mukherji D, Temraz S, Dbouk H, Shamseddine A. Predictors of oxaliplatin-induced hepatotoxicity: Increase in spleen volume or liver fibrosis and steatosis? Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Zaghal A, Tamim H, Habib S, Jaafar R, Mukherji D, Khalife M, Mailhac A, Faraj W. Drain or No Drain Following Pancreaticoduodenectomy: The Unsolved Dilemma. Scand J Surg 2019; 109:228-237. [PMID: 30931801 DOI: 10.1177/1457496919840960] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND AND AIMS There is no consensus regarding the routine placement of intra-abdominal drains after pancreaticoduodenectomy. We aim to determine the effects of intraperitoneal drain placement during pancreaticoduodenectomy on 30-day postoperative morbidity and mortality. METHODS Patients who underwent pancreaticoduodenectomy for pancreatic tumors were identified from the 2014-2015 American College of Surgeons-National Surgical Quality Improvement Program Database. Univariate and multivariate analyses adjusting for known prognostic variables were performed. A subgroup analysis was performed based on the risk for development of postoperative pancreatic leak determined by the pancreatic duct caliber, parenchymal texture, and body mass index. RESULTS A total of 6858 patients with pancreatic tumors who underwent pancreaticoduodenectomy were identified in the 2014-2015 American College of Surgeons-National Surgical Quality Improvement Program Database dataset. In all, 87.4% of patients had intraperitoneal drains placed. A 30-day mortality rate was higher in the no-drain group (2.9% vs. 1.7%, P = 0.003). Patients in the drain group had a higher incidence of overall morbidity (49.5% vs. 41.2%, P = 0.0008), delayed gastric emptying (18.1% vs. 13.7%, P = 0.004), pancreatic fistulae (19.4% vs. 9.9%, P ⩽ 0.0001), and prolonged length of hospital stay over 10 days (43.7% vs. 34.9%, P < 0.0001). Subgroup analysis based on risk categories revealed a higher 30-day mortality rate in the no-drain group among patients with high-risk features (3.1% vs. 1.6%, P = 0.02). Delayed gastric emptying and pancreatic fistula development remained significantly higher in the drain group only in the high-risk category. Prolonged length of hospital stay and composite morbidity remained higher in the drain group regardless of the risk category. CONCLUSION To our knowledge, this is the largest study to date that aims at clarifying the pros and cons of the intraperitoneal drain placement during pancreaticoduodenectomy for pancreatic tumors. We showed a higher 30-day mortality rate if drain insertion was omitted during pancreaticoduodenectomy in patients with softer pancreatic textures, smaller pancreatic duct caliber, and body mass index over 25. Postoperative 30-day morbidity rate was higher if a drain was inserted regardless of the risk category. Further randomized controlled trials with prospective evaluation of stratification factors for fistula risk are needed to establish a clear recommendation.
Collapse
Affiliation(s)
- A Zaghal
- Liver Transplantation and HPB Unit, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon
| | - H Tamim
- Liver Transplantation and HPB Unit, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon
| | - S Habib
- Liver Transplantation and HPB Unit, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon
| | - R Jaafar
- Liver Transplantation and HPB Unit, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon
| | - D Mukherji
- Liver Transplantation and HPB Unit, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon
| | - M Khalife
- Liver Transplantation and HPB Unit, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon
| | - A Mailhac
- Liver Transplantation and HPB Unit, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon
| | - W Faraj
- Liver Transplantation and HPB Unit, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon
| |
Collapse
|
10
|
Temraz S, Hammoud MS, Makki I, Nassif S, Charafeddine M, Mukherji D, Shamseddine A. High proliferation is independently associated with disease progression in metastatic pancreatic adenocarcinoma. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Cheaito K, Bahmad H, Hadadeh O, Hammoud M, Tawil A, El-Sabban M, El-Hajj A, Mukherji D, Abou-Kheir W. PO-439 Establishment and characterisation of prostate cancer patient-derived organoids and cells. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
12
|
Temraz S, Hammoud MS, Zorkot M, Albonji W, Dbouk H, Farhat F, Charafeddine M, Mukherji D, Shamseddine A. Neo-adjuvant FOLFIRINOX in borderline-resectable/locally advanced pancreatic adenocarcinoma: An updated analysis. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Hajj AE, Mansour M, Khalil L, Bulbul M, Mukherji D. Enquête nationale sur la pratique de la surveillance active pour cancer de prostate au Liban. Prog Urol 2017. [DOI: 10.1016/j.purol.2017.07.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
14
|
Assi H, Nohra V, Sukhon F, Moukalled N, Bou Akl I, Mukherji D, Charafeddine M, Abdul Halim N, El Mouhayyar C, Medlej Y, Bou Khalil P. Outcomes of patients with malignancy admitted to the intensive care units (ICU): A prospective study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx388.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Abstract
<p>Core-shell type magnetic nanoparticles are finding attractive applications in biomedicine, from diagnostic to cancer therapy. Both for targeted drug delivery and hyperthermia, as well as a contrast agent used for external biomedical imaging systems, small (< 20 nm) superparamagnetic nanoparticles are desired. Some iron oxide nanoparticle formulations are already approved for human administration as contrast agent for magnetic resonance imaging. However, search continues for nanoparticles with higher saturation magnetisation. Metallic, bi-metallic and intermetallic magnetic nanoparticles are finding attention. Biocompatibility and optimal clearance are important criteria for the medical applications and therefore core-shell type particles are favored, where a biocompatible shell (e.g. polymer, Silica) can prevent inadvertent host reaction with the magnetic core. A recently developed novel synthesis method (electrochemical selective phase dissolution - ESPD), which can produce core-shell magnetic nanoparticles, is reviewed in this paper. ESPD, as the name suggests, uses electro-chemical separation of a phase from metallic alloys to synthesize nanoparticles. It is a versatile method and can be adopted to produce a wide range of nanostructures in addition to the core-shell magnetic nanoparticles.</p>
Collapse
|
16
|
Temraz S, Albonji W, Charafeddine M, Farhat Z, Mukherji D, Shamseddine A. RM-037 Modified GTX second-line therapy in pancreatic adenocarcinoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw201.36] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Hakim A, Hilal L, Mukherji D, Temraz S, Shamseddine A. RM-033 Rectal cancer in patients younger than 40 at AUBMC: tumor characteristics and comparative survival and disease free survival. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw201.32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Temraz S, Albonji W, Charafeddine M, Farhat Z, Mukherji D, Shamseddine A. RM-038 Neo-adjuvant FOLFIRINOX in borderline-resectable/locally advanced pancreatic adenocarcinoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw201.37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Chami H, Faraj W, Yehia Z, Badour S, Sawan P, Rebeiz K, Safa R, Saade C, Ghandour B, Shamseddine A, Mukherji D, Haydar A. Predictors of pneumothorax after CT-guided transthoracic needle lung biopsy: the role of quantitative CT. Clin Radiol 2015; 70:1382-7. [DOI: 10.1016/j.crad.2015.08.003] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2015] [Revised: 07/28/2015] [Accepted: 08/04/2015] [Indexed: 11/30/2022]
|
20
|
Shahait M, Mukherji D, Yacoubian A, Shamseddine A, Khauli R. S151: Inter-regional variability of prostate cancer incidence and mortality rates in the MENA region. ACTA ACUST UNITED AC 2014. [DOI: 10.1016/s1569-9056(14)61707-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
21
|
Zafeiriou Z, Ferraldeschi R, Omlin A, Pezaro C, Mukherji D, Lorente D, Altavilla A, Sideris S, Rescigno P, Mateo J, Bianchini D, Smith A, Lopez RP, Mehra N, Ravi P, Grist E, Tunariu N, Attard G, de Bono J. Sequencing of Docetaxel (D) and Abiraterone Acetate (Aa) for Metastatic Castration-Resistant Prostate Cancer (Mcrpc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu336.39] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Mukherji D, Jabbour M, Saroufim M, Temraz S, Nasr R, Shamseddine A, Tawil A. Pd-L1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node Metastasis. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu337.55] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Mukherji D, Gilles R, Karge L, Strunz P, Beran P, Eckerlebe H, Stark A, Szentmiklosi L, Mácsik Z, Schumacher G, Zizak I, Hofmann M, Hoelzel M, Rösler J. Neutron and synchrotron probes in the development of Co–Re-based alloys for next generation gas turbines with an emphasis on the influence of boron additives. J Appl Crystallogr 2014. [DOI: 10.1107/s1600576714013624] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Nickel-based superalloys are the materials of choice in the hot section of current gas turbines, but they are reaching temperature limits constrained by their melting temperature range. Co–Re alloy development was prompted by a search for new materials for future gas turbines, where the temperature of application will be considerably higher. Addition of the very high melting point refractory metal Re to Co can increase the melting range of Co alloys to much higher temperatures than the commercial Co alloys in use today. The alloy development strategy is first discussed very briefly. In this program, model ternary and quaternary compositions were studied in order to develop a basic understanding of the alloy system.In situneutron and synchrotron measurements (small and wide angle) at high temperatures were extensively used for this purpose and some selected results from thein situmeasurements are presented. In particular, the effect of boron doping in Co–Re–Cr alloys and the stability of the TaC precipitates at high temperatures were investigated. A fine dispersion of TaC precipitates strengthens some Co–Re alloys, and their stability at the application temperature is critical for the long-term creep properties.
Collapse
|
24
|
Pezaro C, Omlin A, Lorente D, Rodrigues DN, Ferraldeschi R, Bianchini D, Mukherji D, Riisnaes R, Altavilla A, Crespo M, Tunariu N, de Bono J, Attard G. Visceral disease in castration-resistant prostate cancer. Eur Urol 2014; 65:270-273. [PMID: 24295792 PMCID: PMC4881819 DOI: 10.1016/j.eururo.2013.10.055] [Citation(s) in RCA: 150] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2013] [Accepted: 10/31/2013] [Indexed: 11/29/2022]
Abstract
Metastatic involvement of the viscera in men with advanced castration-resistant prostate cancer (CRPC) has been poorly characterised to date. In 359 CRPC patients treated between June 2003 and December 2011, the frequency of radiologically detected visceral metastases before death was 32%. Of the 92 patients with computed tomography performed within 3 mo of death, 49% had visceral metastases. Visceral metastases most commonly involved the liver (20%) and lung (13%). Median survival from diagnosis of visceral disease was 7.1 mo (95% confidence interval, 5.9-8.3). Survival was affected by the degree of bone involvement at detection of visceral disease, varying from 6.1 mo in men with more than six bone metastases to 18.2 mo in men with no bone metastases (p=0.001). Heterogeneity was noted in clinical phenotypes and prostate-specific antigen trends at development of visceral metastases. Visceral metastases are now more commonly detected in men with CRPC, likely due to the introduction of novel survival-prolonging treatments.
Collapse
Affiliation(s)
- C Pezaro
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - A Omlin
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - D Lorente
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - D Nava Rodrigues
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - R Ferraldeschi
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - D Bianchini
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - D Mukherji
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - R Riisnaes
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - A Altavilla
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - M Crespo
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - N Tunariu
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - J de Bono
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - G Attard
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| |
Collapse
|
25
|
Omlin A, Pezaro CJ, Zaidi S, Lorente D, Mukherji D, Bianchini D, Ferraldeschi R, Sandhu S, Dearnaley D, Parker C, Van As N, de Bono JS, Attard G. Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. Br J Cancer 2013; 109:1079-84. [PMID: 23928659 PMCID: PMC3778298 DOI: 10.1038/bjc.2013.446] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2013] [Revised: 07/05/2013] [Accepted: 07/10/2013] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Abiraterone is a standard treatment for men with castration-resistant prostate cancer (CRPC). We evaluated the antitumour activity of abiraterone following the synthetic oestrogen diethylstilboestrol (DES). METHODS Castration-resistant prostate cancer patients treated with abiraterone were identified. Demographics, response variables and survival data were recorded. RESULTS Two-hundred and seventy-four patients received abiraterone, 114 (41.6%) after DES. Pre-chemotherapy abiraterone resulted in ≥50% PSA declines in 35/41 (85.4%) DES-naïve and 20/27 (74.1%) DES-treated patients. Post-docetaxel abiraterone resulted in ≥50% PSA declines in 40/113 (35.4%) DES-naïve and 23/81 (28.4%) DES-treated patients. Time to PSA progression was similar regardless of prior DES. CONCLUSION Abiraterone has important antitumour activity in men with CRPC even after DES exposure.
Collapse
Affiliation(s)
- A Omlin
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Pezaro C, Mukherji D, Tunariu N, Cassidy AM, Omlin A, Bianchini D, Seed G, Reid AHM, Olmos D, de Bono JS, Attard G. Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. Br J Cancer 2013; 109:325-31. [PMID: 23807167 PMCID: PMC3721397 DOI: 10.1038/bjc.2013.340] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2013] [Revised: 06/04/2013] [Accepted: 06/09/2013] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND Standard medical castration reduces muscle mass. We sought to characterize body composition changes in men undergoing maximal androgen suppression with and without exogenous gluocorticoids. METHODS Cross-sectional areas of total fat, visceral fat and muscle were measured on serial CT scans in a post-hoc analysis of patients treated in Phase I/II trials with abiraterone followed by abiraterone and dexamethasone 0.5 mg daily. Linear mixed regression models were used to account for variations in time-on-treatment and baseline body mass index (BMI). RESULTS Fifty-five patients received a median of 7.5 months abiraterone followed by 5.4 months abiraterone and dexamethasone. Muscle loss was observed on single-agent abiraterone (maximal in patients with baseline BMI >30, -4.3%), but no further loss was observed after addition of dexamethasone. Loss of visceral fat was also observed on single-agent abiraterone, (baseline BMI >30 patients -19.6%). In contrast, addition of dexamethasone led to an increase in central visceral and total fat and BMI in all the patients. INTERPRETATION Maximal androgen suppression was associated with loss of muscle and visceral fat. Addition of low dose dexamethasone resulted in significant increases in visceral and total fat. These changes could have important quality-of-life implications for men treated with abiraterone.
Collapse
Affiliation(s)
- C Pezaro
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - D Mukherji
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - N Tunariu
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - A M Cassidy
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - A Omlin
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - D Bianchini
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - G Seed
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - A H M Reid
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - D Olmos
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - J S de Bono
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| | - G Attard
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
| |
Collapse
|
27
|
Elias E, Mukherji D, Faraj W, Alameddine R, Saleh A, El Saghir N, Shamseddine A. 43 Effect of Nodal Status in Triple Negative Breast Cancer – Survival Outcomes From a Tertiary Center. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70111-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
28
|
Kularatne BY, Ayres BE, Mukherji D, Watkin N, Lam W, Perry M, Pickering LM. Chemotherapy for squamous cell carcinoma of the penis: An 8-year, single-institution experience. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
222 Background: Penile cancer is a rare malignancy affecting approximately 400 men per year in the United Kingdom. There are relatively limited data regarding the role of chemotherapy, although it may be considered in the adjuvant setting for high-risk disease and for palliation of metastatic disease. Methods: Patients treated with chemotherapy between June 2002 and March 2010 were identified from our prospectively maintained institutional database. Regimens were recorded and toxicity documented according to the Common Toxicity Criteria version 4.0. Response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 until 2009 and then version 1.1. Results: Twenty patients received chemotherapy either for adjuvant treatment (n=6) or for metastatic disease (n=14). Median age was 59 (range 33-80). Different regimens were used over the time period. In the adjuvant setting 4-6 cycles of chemotherapy were planned and all patients received cisplatin in combination with 5-FU or capecitabine. Five (83%) completed planned treatment with no grade 3 or 4 toxicities. One patient stopped after 2 cycles due to deteriorating renal function. Patients remained disease free at up to 22 months follow-up. In the metastatic setting, 10 patients received cisplatin and capecitabine, 1 cisplatin and 5-FU and 1 carboplatin and capecitabine. Of these 12 patients, 2 (17%) had partial response as their best response, 4 (33%) had stable disease (SD) and 6 (50%) had progressive disease (PD). Three patients (25%) experienced pulmonary embolism, 1 of whom died. Two (17%) developed grade 3 neutropenia. One patient received carboplatin, methotrexate and bleomycin with PD after 3 cycles and developed grade 3 neutropenia, stomatitis, and diarrhea. One patient received 3 cycles of paclitaxel, ifosfamide, and cisplatin with SD and no grade 3 or 4 toxicities. Conclusions: Combination chemotherapy can be delivered with acceptable toxicity in the adjuvant setting. In the metastatic setting response rates were disappointing and treatments were associated with greater toxicity. New treatments are urgently required to improve outcomes in this difficult malignancy. [Table: see text]
Collapse
Affiliation(s)
| | - B. E. Ayres
- St. George's Hospital, London, United Kingdom
| | - D. Mukherji
- St. George's Hospital, London, United Kingdom
| | - N. Watkin
- St. George's Hospital, London, United Kingdom
| | - W. Lam
- St. George's Hospital, London, United Kingdom
| | - M. Perry
- St. George's Hospital, London, United Kingdom
| | | |
Collapse
|
29
|
Müllner P, Chernenko VA, Mukherji D, Kostorz G. Cyclic magnetic-field -induced deformation and magneto-mechanical fatigue of Ni-Mn-Ga ferromagnetic martensites. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-785-d12.2] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACTFour Ni-Mn-Ga single crystals exhibiting modulated 10M and 14M martensites were exposed to rotating magnetic fields of 1 and 2 T. Large periodic magnetic-field-induced strains were obtained for crystals that had been subjected to a mechanical stress while the martensite formed on cooling and to deformation in a magnetic field prior to the experiments with rotating field. A reduction of the magnetic-field-induced strain and fracture occurred when the field-induced strain was close to the transformation strain whereas a constant magneto-mechanical response was detected over more than 10 million field cycles when the field-induced strain was small. The cyclic magneto-mechanical response is related to the interaction of groups of twinning dislocations and twin boundaries. If the dislocations move in large groups, they nucleate cracks at twin boundaries. If the dislocations move in small groups, no cracks are formed resulting in a long lifetime.
Collapse
|
30
|
|
31
|
Abstract
Internal defects and strain in nanoparticles can influence their properties and therefore measuring these values is relevant. Powder diffraction techniques (neutron and synchrotron) are successfully used to characterize internal strain in the core-shell Ni(3)Si(Al)-SiO(x) nanoparticles having mean diameters of approximately 80 nm. The nanoparticles, which are strain-free after extraction from the bulk alloys, develop internal strain on heating. Both micro- and macro-strains can be measured from the analysis of Bragg peak shift and broadening. It is identified that differences in thermal expansion coefficient of the metallic core and the amorphous shell of the nanoparticles, as well as partial disordering of the L1(2) ordered core phase, are the main causes of strain evolution. Synchrotron measurements also detected partial crystallization of the amorphous silica shell.
Collapse
Affiliation(s)
- G Pigozzi
- Laboratorium für Nanometallurgie, ETH Zurich, Wolfgangpaulistrasse 10, CH-8093 Zürich, Switzerland.
| | | | | | | | | |
Collapse
|
32
|
Rudman SM, Comins C, Mukherji D, Coffey M, Mettinger K, Protheroe A, Harrington KJ, Pandha H, Spicer JF. Results of a phase I study to evaluate the feasibility, safety, and biological effects of intravenous administration of wild-type reovirus with docetaxel to patients with advanced malignancies. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e13524] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13524 Background: Reovirus has minimal pathogenicity in humans but selectively replicates in cells with activated Ras. Wild- type reovirus serotype 3 Dearing strain (Reolysin) has selective antitumor activity in vitro, in murine models, and after systemic delivery in humans in phase 1 trials. Synergistic tumour kill has been observed combining reovirus with taxanes in a range of cancer cell lines and in vivo. Methods: Patients were treated in an open-label, dose-escalating, phase I trial and received 3- weekly 75mg/m2 docetaxel i.v. and reovirus i.v. (day 1–5 of first week inclusive). Reovirus was administered at a starting dose of 3x109 tissue culture infectious dose (TCID50) and then increased to 1 x 1010 and 3 x 1010 TCID50. Primary endpoints were to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and to recommend a dose and schedule for future investigation. Secondary endpoints were to evaluate pharmacokinetics, neutralizing antibody development, cell- mediated immune response and anti-tumour activity. Results: 17 patients were treated (15 males, median age 60 years). No MTD has been reached. DLT's observed were G4 neutropenia (and a recurrent perianal abcess) and G3 rise in AST. Other toxicities observed were fatigue, hypotension and neutropenic sepsis. At present, 5 patients remain on treatment. We have observed 2 partial responses (breast and gastric carcinoma) and 10 patients had stable disease as best response. Conclusions: Reovirus is well tolerated when administered in combination with intravenous docetaxel, with predictable toxicity observed. The recommended dose has been defined at 3x1010 TCID50 and phase II studies are planned. Objective radiological evidence of anticancer activity for this combination has been observed. [Table: see text]
Collapse
Affiliation(s)
- S. M. Rudman
- Guy's Hospital, London, United Kingdom; University of Surrey, Guildford, United Kingdom; Oncolytics Biotech Inc., Calgary, AB, Canada; Churchill Hospital, Oxford, United Kingdom; Institute of Cancer Research, London, United Kingdom
| | - C. Comins
- Guy's Hospital, London, United Kingdom; University of Surrey, Guildford, United Kingdom; Oncolytics Biotech Inc., Calgary, AB, Canada; Churchill Hospital, Oxford, United Kingdom; Institute of Cancer Research, London, United Kingdom
| | - D. Mukherji
- Guy's Hospital, London, United Kingdom; University of Surrey, Guildford, United Kingdom; Oncolytics Biotech Inc., Calgary, AB, Canada; Churchill Hospital, Oxford, United Kingdom; Institute of Cancer Research, London, United Kingdom
| | - M. Coffey
- Guy's Hospital, London, United Kingdom; University of Surrey, Guildford, United Kingdom; Oncolytics Biotech Inc., Calgary, AB, Canada; Churchill Hospital, Oxford, United Kingdom; Institute of Cancer Research, London, United Kingdom
| | - K. Mettinger
- Guy's Hospital, London, United Kingdom; University of Surrey, Guildford, United Kingdom; Oncolytics Biotech Inc., Calgary, AB, Canada; Churchill Hospital, Oxford, United Kingdom; Institute of Cancer Research, London, United Kingdom
| | - A. Protheroe
- Guy's Hospital, London, United Kingdom; University of Surrey, Guildford, United Kingdom; Oncolytics Biotech Inc., Calgary, AB, Canada; Churchill Hospital, Oxford, United Kingdom; Institute of Cancer Research, London, United Kingdom
| | - K. J. Harrington
- Guy's Hospital, London, United Kingdom; University of Surrey, Guildford, United Kingdom; Oncolytics Biotech Inc., Calgary, AB, Canada; Churchill Hospital, Oxford, United Kingdom; Institute of Cancer Research, London, United Kingdom
| | - H. Pandha
- Guy's Hospital, London, United Kingdom; University of Surrey, Guildford, United Kingdom; Oncolytics Biotech Inc., Calgary, AB, Canada; Churchill Hospital, Oxford, United Kingdom; Institute of Cancer Research, London, United Kingdom
| | - J. F. Spicer
- Guy's Hospital, London, United Kingdom; University of Surrey, Guildford, United Kingdom; Oncolytics Biotech Inc., Calgary, AB, Canada; Churchill Hospital, Oxford, United Kingdom; Institute of Cancer Research, London, United Kingdom
| |
Collapse
|
33
|
|
34
|
Mukherji D, Lackner J, Wanderka N, Kardjilov N, Näth O, Jäger S, Schmitz F, Rösler J. Coating of meso-porous metallic membranes with oriented channel-like fine pores by pulsed laser deposition. Nanotechnology 2008; 19:065706. [PMID: 21730712 DOI: 10.1088/0957-4484/19/6/065706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
There is increasing demand to functionalize meso- and nanoporous materials by coating and make the porous substrate biocompatible or environmentally friendly. However, coating on a meso-porous substrate poses great challenges, especially if the pore aspect ratio is high. We adopted the pulsed laser deposition (PLD) method to coat Ni(3)Al-based meso-porous membranes, which were fabricated from a single-crystal Ni-based superalloy by a unique selective phase dissolution technique. These membranes were about 250 µm thick and had channel-like pores (∼200 nm wide) with very high aspect ratio. Two different coating materials, i.e. diamond-like carbon (DLC) and titanium, were used to coat these membranes. High energy C or Ti ions, produced in the plasma plume by the PLD process, penetrated the channel-like pores and deposited coatings on the pore walls deep inside the membrane. The thickness and the quality of coatings on the pore walls were examined using the dual-beam system. The coating thickness, of the order of 50 nm, was adherent to the pore walls and was quite uniform at different depths. The carbon and the Ti deposition behaved quite similarly. The preliminary experiments showed that the PLD is an adequate method for coating fine open cavities of complex geometry. Simulations based on stopping and the range of ions in matter (SRIM) calculations helped in understanding the deposition processes on pore walls at great depths.
Collapse
Affiliation(s)
- D Mukherji
- Technische Universität Braunschweig, IfW, Langer Kamp 8, D-38106 Braunschweig, Germany
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Mukherjee E, Mukherji D, Jayawardene SA, Kon SP. Tumor lysis syndrome and acute renal failure ? an increasing spectrum of presentations. Clin Nephrol 2007; 68:186-9. [PMID: 17915624 DOI: 10.5414/cnp68186] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Tumor lysis syndrome has historically been associated with hyperuricemia and uric acid crystal deposition. We present three cases of tumor lysis syndrome resulting in renal failure in the context of normouricema, highlighting the spectrum of clinical presentations and mechanisms of renal damage. Two cases occurred following the treatment of hematological malignancies and were associated with hyperphosphatemia; the third resulted from ischemic necrosis following transarterial chemoembolization of a hepatic tumor. We also discuss the role of renal biopsy in the investigation of tumor lysis syndrome.
Collapse
Affiliation(s)
- E Mukherjee
- Department of Nephrology, Kings College Hospital, London, United Kingdom.
| | | | | | | |
Collapse
|
36
|
Kindrachuk V, Wanderka N, Banhart J, Mukherji D, Del Genovese D, Rösler J. Microchemical characterization of phases in Inconel 706 and DT 706 alloys after aging. SURF INTERFACE ANAL 2007. [DOI: 10.1002/sia.2515] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
37
|
Pigozzi G, Mukherji D, Gilles R, Barbier B, Kostorz G. Ni(3)Si(Al)/a-SiO(x) core-shell nanoparticles: characterization, shell formation, and stability. Nanotechnology 2006; 17:4195-4203. [PMID: 21727559 DOI: 10.1088/0957-4484/17/16/033] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
We have used an electrochemical selective phase dissolution method to extract nanoprecipitates of the Ni(3)Si-type intermetallic phase from two-phase Ni-Si and Ni-Si-Al alloys by dissolving the matrix phase. The extracted nanoparticles are characterized by transmission electron microscopy, energy-dispersive x-ray spectrometry, x-ray powder diffraction, and electron powder diffraction. It is found that the Ni(3)Si-type nanoparticles have a core-shell structure. The core maintains the size, the shape, and the crystal structure of the precipitates that existed in the bulk alloys, while the shell is an amorphous phase, containing only Si and O (SiO(x)). The shell forms around the precipitates during the extraction process. After annealing the nanoparticles in nitrogen at 700 °C, the tridymite phase recrystallizes within the shell, which remains partially amorphous. In contrast, on annealing in air at 1000 °C, no changes in the composition or the structure of the nanoparticles occur. It is suggested that the shell forms after dealloying of the matrix phase, where Si atoms, the main constituents of the shell, migrate to the surface of the precipitates.
Collapse
Affiliation(s)
- G Pigozzi
- ETH Zurich, Institute of Applied Physics, CH-8093, Zürich, Switzerland
| | | | | | | | | |
Collapse
|
38
|
Bharati S, Demarchi DA, Mukherji D, Vasulu TS, Bharati P. Spatial patterns of anthropometric variation in India with reference to geographic, climatic, ethnic and linguistic backgrounds. Ann Hum Biol 2006; 32:407-44. [PMID: 16147394 DOI: 10.1080/03014460500097443] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
BACKGROUND Anthropometric variation can be fruitfully utilized to investigate microevolutionary processes. Anthropometric variations in the Indian subcontinent based on stature and three indices (Cephalic Index, Nasal Index, and Total Facial Index) are highly variable and discriminative among populations across geographical regions. AIMS Anthropometric variation in stature, Cephalic Index (CI), Nasal Index (NI) and Total Facial Index (TFI) were investigated with respect to ethnic, linguistic, geographical and climatic affiliation, across the Indian subcontinent. SUBJECTS AND METHODS Published data on anthropometric variations of 531 populations from the Indian subcontinent were analysed using discriminant analysis and spatial autocorrelation analysis. RESULTS Discriminant analysis of the four anthropometric variables shows that stature and NI are good discriminators for populations of different languages. Stature, NI and CI discriminate well among populations of diverse ethnic origin and climatic conditions in different regions. TFI is not a good discriminator for populations of diverse ethnic, linguistic and climatic attributes. Spatial autocorrelation analysis showed significant departure from randomness, suggesting geographic structuring. The Moran's I estimate is positive and statistically significant for the four variables at low distances but exhibits significant negative association at higher values. CONCLUSION The results suggest geographical clines for the four anthropometric variables and indicate the influence of population structure on the studied variables.
Collapse
Affiliation(s)
- S Bharati
- Indian Statistical Institute, Kolkata, India
| | | | | | | | | |
Collapse
|
39
|
Pattnaik KP, Mohapatra S, Mohanty M, Mohapatra BN, Patel D, Mukherji D. Clinical orientation of undergraduate pharmacology practicals: An intervention study. Indian J Pharmacol 2006. [DOI: 10.4103/0253-7613.25809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
40
|
Mukherji D, Pigozzi G, Schmitz F, Näth O, Rösler J, Kostorz G. Nano-structured materials produced from simple metallic alloys by phase separation. Nanotechnology 2005; 16:2176-2187. [PMID: 20817992 DOI: 10.1088/0957-4484/16/10/034] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
A method which is able to produce different types of nano-structured materials, namely nano-particles, nano-structured surfaces and nano-porous membranes, from two-phase metallic alloys is reviewed. The new process first establishes nano-structures in the bulk alloy and then separates them by selective phase dissolution. Variation in processing makes it possible to produce different types of nano-structure even from the same alloy. The process can be applied to many different alloy systems. An overview is presented emphasizing the versatility of the process with examples of different nano-structure types that can be produced. Further, the new method is discussed in relation to similar processes (specifically, electrochemical processes) which have been used for nano-structure synthesis.
Collapse
Affiliation(s)
- D Mukherji
- ETH Zurich, Institute of Applied Physics, CH-8093 Zurich, Switzerland
| | | | | | | | | | | |
Collapse
|
41
|
Wanderka N, Naundorf V, Banhart J, Mukherji D, Genovesse DD, Rösler J. Microstructural characterization of Inconel 706 alloy. SURF INTERFACE ANAL 2004. [DOI: 10.1002/sia.1696] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
42
|
Gilles R, Strunz P, Mukherji D, Roth S, Wiedenmann A, Roesler J, Fuess H. Small-angle scattering, a tool to characterize Ni-base superalloys at high temperature. Acta Crystallogr A 2002. [DOI: 10.1107/s0108767302086129] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
43
|
|
44
|
Swain TR, Das M, Kanungo S, Mukherji D, Mishra SS, Das MC. A comparative study on the effect of felodipine and propranolol on serum lipid profile of rabbits. Indian J Physiol Pharmacol 1997; 41:269-74. [PMID: 10232772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/13/2023]
Abstract
Effect of felodipine on serum lipids of rabbits was studied and was compared with that of propranolol. Lipid parameters were estimated at basal (0 wk), end of 4th and 16th week of diet/drug administration by using standard kits for analysis. There was a significant increase in mean serum cholesterol, TG, VLDLc, LDLC and decrease in HDLc, (P<0.05) in the group of rabbits receiving Atherogenic diet (AD)/Propranolol. This effect was maximally observed in rabbits receiving both AD and propranolol. This change was satisfactorily prevented when felodipine was administered from very beginning (P<0.001). In addition, there was a significant increase in HDLc (28.89%) of rabbits receiving felodipine from beginning. Thus both AD and propranolol have dyslipidemic effect and early administration of felodipine favorably changes all lipid parameters.
Collapse
Affiliation(s)
- T R Swain
- P.G. Department of Pharmacology, S.C.B. Medical College, Cuttack
| | | | | | | | | | | |
Collapse
|
45
|
Mukherji D, Jiao F, Chen W, Wahi R. Stacking fault formation in γ′ phase during monotonic deformation of IN738LC at elevated temperatures. ACTA ACUST UNITED AC 1991. [DOI: 10.1016/0956-7151(91)90237-u] [Citation(s) in RCA: 64] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
46
|
Mukherji D. Effect of family planning, economy and education on infant mortality. Man India 1988; 68:252-7. [PMID: 12342056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]
Abstract
"There is an assumption that family planning leads to less infant mortality, and [that a] lower rate of infant mortality will lead toward the evolution of small family. The present paper, based on the data collected from 472 eligible couples from a suburban area of West Bengal, does not reveal any such strong relation between family planning and infant mortality. The data have also been examined in the perspective of familial economic status and formal educational standard of the mothers concerned."
Collapse
|
47
|
Kant L, Mukherji D. Childhood leprosy. Indian Pediatr 1987; 24:105-7. [PMID: 3666937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
48
|
|
49
|
Kant L, Mukherji D. AIDS surveillance and the pediatrician. Indian Pediatr 1986; 23:85-7. [PMID: 3710573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
50
|
Mukherji D, Sita K. Spatial patterns of out-migration in Maharashtra: 1961-71. Popul Geogr 1982; 4:76-80. [PMID: 12179015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]
Abstract
In view of the importance of migration in Maharashtra state. India an attempt is made to identify the areas of out-migration, and to assess the probable causes for it. The analysis is confined to the decade 1961-1971 and based on secondary data, with the taluka as the unit of analysis. The total number of births and deaths in each taluka for the period of study was complied and enabled the natural increase of population to be computed. A comparison of this with the actual increase as indicated by the census made it possible to identify the areas of out-migration. The study revealed that the out-migration talukas were located in 3 areas and that the relative significance of out-migration varied. The analysis indicated that the causes of out-migration were probably unfavorable relief efforts, susceptibility to drought, closure of household industries, and the 'pull' effect of metropolitan centers like Bombay.
Collapse
|